pdf. Revised 06/2022. 42. Brenner, A. et al. At-12: Phase 1/2 Study of Th-302, Investigational Hypoxia-Activated Prodrug, and Bevacizumab in Patients With Bevacizumab-Refractory Recurrent Glioblastoma. Neuro On
Revised19 August 2010 Accepted09 September 2010 Published19 October 2010 Issue Date09 November 2010 DOIhttps://doi.org/10.1038/sj.bjc.6605937 Share this article Anyone you share the following link with will be able to read this content:Get shareable link Provided by the Springer Nature SharedIt...
pdf. Revised 06/2022. 42. Brenner, A. et al. At-12: Phase 1/2 Study of Th-302, Investigational Hypoxia-Activated Prodrug, and Bevacizumab in Patients With Bevacizumab-Refractory Recurrent Glioblastoma. Neuro Oncol. 16, 12 (2014). 43. Singh, H. & Leyton, V. J. Abstract P062: The ...
As life expectancy in developed countries continues to rise, the incidence of glioma among elderly patients is expected to increase significantly in the coming years [15]. This demographic shift may lead to a doubling of GBM cases in patients aged 65 and older over the next two decades, with...
The end points were revised prior to the company being unblinded to the data. End-point revisions have been approved by the FDA in several clinical trials. CONFLICT OF INTEREST: None Reported READ MORE December 22, 2022 The need to present complete data from the placebo arm and to control ...
Additionally eligible patients had good performance status, life expectancy ≥3 months, recovery from prior trAE grade ≥2, as well as good organ and hematological function. Exclusion criteria excluded patients receiving coumadin anticoagulation, enzyme-inducing anti-epileptic agents, biologic agents (...
The discovery of cellular tumor networks in glioblastoma, with routes of malignant communication extending far beyond the detectable tumor margins, has highlighted the potential of supramarginal resection strategies. Retrospective data suggest that these
life expectancy ≥3 months, recovery from prior trAE grade ≥2, as well as good organ and hematological function. Exclusion criteria excluded patients receiving coumadin anticoagulation, enzyme-inducing anti-epileptic agents, biologic agents (within 21 days of first dose), or prior SG. Moreover, ...
Despite a growing number of investigations exploring the relationship between age, comorbidities, and the prognosis of GBM patients, to our knowledge this is the first investigation assessing the relationship between the CAC and life expectancy of patients affected by this deadly disease. In 2019, Vil...
Submission received: 23 June 2023 / Revised: 26 July 2023 / Accepted: 16 August 2023 / Published: 27 August 2023 (This article belongs to the Special Issue Personalized Medicine in Brain Tumors)Download keyboard_arrow_down Browse Figures Versions Notes Abstract HDAC inhibitors (HDACi) hold ...